$CELZ
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
Stock
$celz
2023 Q2 Form 10-Q Financial Statement
#000147793223003347 Filed on May 12, 2023
Income Statement
| Concept | 2023 Q2 | 2023 Q1 | 2022 Q1 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $15.00K |
| YoY Change | -100.0% | ||
| Cost Of Revenue | $0.00 | $0.00 | $6.791K |
| YoY Change | -100.0% | ||
| Gross Profit | $0.00 | $0.00 | $8.209K |
| YoY Change | -100.0% | ||
| Gross Profit Margin | 54.73% | ||
| Selling, General & Admin | $859.5K | $771.0K | $1.130M |
| YoY Change | -22.45% | -31.77% | 302.27% |
| % of Gross Profit | 13766.07% | ||
| Research & Development | $309.5K | $319.0K | $10.00K |
| YoY Change | -53.09% | 3090.29% | |
| % of Gross Profit | 121.82% | ||
| Depreciation & Amortization | $23.02K | $23.02K | $23.02K |
| YoY Change | 0.0% | 0.0% | 0.0% |
| % of Gross Profit | 280.42% | ||
| Operating Expenses | $1.192M | $1.113M | $1.163M |
| YoY Change | -33.45% | -4.3% | 282.67% |
| Operating Profit | -$1.192M | -$1.113M | -$1.155M |
| YoY Change | -33.45% | -3.62% | 279.97% |
| Interest Expense | $89.91K | $50.00 | $0.00 |
| YoY Change | -100.0% | ||
| % of Operating Profit | |||
| Other Income/Expense, Net | $89.91K | $61.15K | $0.00 |
| YoY Change | -100.0% | ||
| Pretax Income | -$1.102M | -$1.052M | -$1.155M |
| YoY Change | -38.47% | -8.91% | -104.15% |
| Income Tax | $0.00 | $0.00 | $0.00 |
| % Of Pretax Income | |||
| Net Earnings | -$1.102M | -$1.052M | -$1.155M |
| YoY Change | -38.47% | -8.91% | -104.15% |
| Net Earnings / Revenue | -7699.13% | ||
| Basic Earnings Per Share | -$0.18 | ||
| Diluted Earnings Per Share | -$0.78 | -$0.07 | -$0.18 |
| COMMON SHARES | |||
| Basic Shares Outstanding | 14.08M shares | 14.08M shares | 6.454M shares |
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2023 Q2 | 2023 Q1 | 2022 Q1 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $3.990M | $9.516M | $9.147M |
| YoY Change | -82.55% | 4.04% | 3224.6% |
| Cash & Equivalents | $3.990M | $9.516M | $9.147M |
| Short-Term Investments | |||
| Other Short-Term Assets | $9.735M | $5.287M | $64.96K |
| YoY Change | 14885.99% | 8039.16% | |
| Inventory | $10.19K | $10.19K | $14.15K |
| Prepaid Expenses | |||
| Receivables | $0.00 | ||
| Other Receivables | $0.00 | ||
| Total Short-Term Assets | $13.73M | $14.81M | $9.226M |
| YoY Change | -40.15% | 60.56% | 3253.36% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | |||
| YoY Change | |||
| Goodwill | |||
| YoY Change | |||
| Intangibles | |||
| YoY Change | |||
| Long-Term Investments | |||
| YoY Change | |||
| Other Assets | $3.280K | $3.280K | $3.281K |
| YoY Change | 0.0% | -0.03% | |
| Total Long-Term Assets | $392.8K | $415.9K | $507.9K |
| YoY Change | -18.99% | -18.13% | -14.88% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $13.73M | $14.81M | $9.226M |
| Total Long-Term Assets | $392.8K | $415.9K | $507.9K |
| Total Assets | $14.13M | $15.23M | $9.734M |
| YoY Change | -39.71% | 56.46% | 1016.44% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $344.4K | $353.4K | $335.7K |
| YoY Change | 10.86% | 5.29% | -5.71% |
| Accrued Expenses | $39.92K | $39.92K | $29.92K |
| YoY Change | -38.51% | 33.42% | -55.84% |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | -100.0% | ||
| Long-Term Debt Due | |||
| YoY Change | |||
| Total Short-Term Liabilities | $398.5K | $407.5K | $379.8K |
| YoY Change | 2.24% | 7.3% | -88.54% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Other Long-Term Liabilities | |||
| YoY Change | |||
| Total Long-Term Liabilities | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $398.5K | $407.5K | $379.8K |
| Total Long-Term Liabilities | $0.00 | $0.00 | $0.00 |
| Total Liabilities | $398.5K | $407.5K | $379.8K |
| YoY Change | 2.24% | 7.3% | -88.54% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$55.97M | -$54.86M | -$44.82M |
| YoY Change | 20.06% | 22.4% | |
| Common Stock | $1.431K | $14.08K | $6.521K |
| YoY Change | -89.75% | 115.87% | |
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $13.73M | $14.82M | $9.354M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $14.13M | $15.23M | $9.734M |
| YoY Change | -39.71% | 56.46% | 1016.44% |
Cashflow Statement
| Concept | 2023 Q2 | 2023 Q1 | 2022 Q1 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$1.102M | -$1.052M | -$1.155M |
| YoY Change | -38.47% | -8.91% | -104.15% |
| Depreciation, Depletion And Amortization | $23.02K | $23.02K | $23.02K |
| YoY Change | 0.0% | 0.0% | 0.0% |
| Cash From Operating Activities | -$986.7K | -$3.842M | -$1.577M |
| YoY Change | -43.79% | 143.62% | 257.15% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | |||
| YoY Change | |||
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | -$4.540M | $5.037M | $0.00 |
| YoY Change | |||
| Cash From Investing Activities | -$4.540M | $5.037M | $0.00 |
| YoY Change | |||
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | |||
| YoY Change | |||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | 0.000 | $0.00 | $0.00 |
| YoY Change | -100.0% | -100.0% | |
| NET CHANGE | |||
| Cash From Operating Activities | -986.7K | -$3.842M | -$1.577M |
| Cash From Investing Activities | -4.540M | $5.037M | $0.00 |
| Cash From Financing Activities | 0.000 | $0.00 | $0.00 |
| Net Change In Cash | -5.527M | $1.196M | -$1.577M |
| YoY Change | -140.29% | -175.83% | -990.29% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$986.7K | -$3.842M | -$1.577M |
| Capital Expenditures | |||
| Free Cash Flow | |||
| YoY Change |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2023Q1 | dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001187953 | |
| CY2023Q1 | dei |
Amendment Flag
AmendmentFlag
|
false | |
| CY2023Q1 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | |
| CY2023Q1 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q1 | |
| CY2023Q1 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2023 | |
| CY2022Q4 | us-gaap |
Common Stock No Par Value
CommonStockNoParValue
|
0.001 | |
| CY2022Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
50000000000 | shares |
| CY2022Q1 | us-gaap |
Deferred Revenue
DeferredRevenue
|
0 | usd |
| CY2023Q1 | dei |
Document Type
DocumentType
|
10-Q | |
| CY2023Q1 | dei |
Document Quarterly Report
DocumentQuarterlyReport
|
true | |
| CY2023Q1 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2023-03-31 | |
| CY2023Q1 | dei |
Document Transition Report
DocumentTransitionReport
|
false | |
| CY2023Q1 | dei |
Entity File Number
EntityFileNumber
|
000-53500 | |
| CY2023Q1 | dei |
Entity Registrant Name
EntityRegistrantName
|
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. | |
| CY2023Q1 | dei |
Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
|
NV | |
| CY2023Q1 | dei |
Entity Tax Identification Number
EntityTaxIdentificationNumber
|
87-0622284 | |
| CY2023Q1 | dei |
Entity Address Address Line1
EntityAddressAddressLine1
|
211 E Osborn Road | |
| CY2023Q1 | dei |
Entity Address City Or Town
EntityAddressCityOrTown
|
Phoenix | |
| CY2023Q1 | dei |
Entity Address State Or Province
EntityAddressStateOrProvince
|
AZ | |
| CY2023Q1 | dei |
Entity Address Postal Zip Code
EntityAddressPostalZipCode
|
85012 | |
| CY2023Q1 | dei |
City Area Code
CityAreaCode
|
480 | |
| CY2023Q1 | dei |
Local Phone Number
LocalPhoneNumber
|
399-2822 | |
| CY2023Q1 | dei |
Security12b Title
Security12bTitle
|
Common Stock, par value $0.001 per share | |
| CY2023Q1 | dei |
Trading Symbol
TradingSymbol
|
CELZ | |
| CY2023Q1 | dei |
Security Exchange Name
SecurityExchangeName
|
NASDAQ | |
| CY2023Q1 | dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | |
| CY2023Q1 | dei |
Entity Interactive Data Current
EntityInteractiveDataCurrent
|
Yes | |
| CY2023Q1 | dei |
Entity Filer Category
EntityFilerCategory
|
Non-accelerated Filer | |
| CY2023Q1 | dei |
Entity Small Business
EntitySmallBusiness
|
true | |
| CY2023Q1 | dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
false | |
| CY2023Q1 | dei |
Entity Shell Company
EntityShellCompany
|
false | |
| CY2023Q2 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
14076238 | shares |
| CY2023Q1 | us-gaap |
Due To Related Parties Current
DueToRelatedPartiesCurrent
|
14194 | usd |
| CY2022Q4 | us-gaap |
Due To Related Parties Current
DueToRelatedPartiesCurrent
|
14194 | usd |
| CY2023Q1 | us-gaap |
Cost Of Revenue
CostOfRevenue
|
0 | usd |
| CY2023Q1 | us-gaap |
Gross Profit
GrossProfit
|
0 | usd |
| CY2022Q1 | us-gaap |
Gross Profit
GrossProfit
|
8209 | usd |
| CY2023Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
319029 | usd |
| CY2022Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
10000 | usd |
| CY2023Q1 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
771020 | usd |
| CY2022Q1 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
1130057 | usd |
| CY2023Q1 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
23021 | usd |
| CY2022Q1 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
23021 | usd |
| CY2023Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
1113070 | usd |
| CY2022Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
1163078 | usd |
| CY2023Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-1113070 | usd |
| CY2022Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-1154869 | usd |
| CY2023Q1 | us-gaap |
Interest Expense
InterestExpense
|
50 | usd |
| CY2022Q1 | us-gaap |
Interest Expense
InterestExpense
|
0 | usd |
| CY2023Q1 | us-gaap |
Interest And Other Income
InterestAndOtherIncome
|
61197 | usd |
| CY2022Q1 | us-gaap |
Interest And Other Income
InterestAndOtherIncome
|
0 | usd |
| CY2023Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
61147 | usd |
| CY2022Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
0 | usd |
| CY2023Q1 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-1051923 | usd |
| CY2022Q1 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-1154869 | usd |
| CY2023Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | usd |
| CY2022Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-1051923 | usd |
| CY2022Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-1154869 | usd |
| CY2023Q1 | celz |
Earnings Per Share Basics And Diluted
EarningsPerShareBasicsAndDiluted
|
-0.07 | |
| CY2022Q1 | celz |
Earnings Per Share Basics And Diluted
EarningsPerShareBasicsAndDiluted
|
-0.18 | |
| CY2023Q1 | celz |
Weighted Average Number Of Share Outstanding Basic
WeightedAverageNumberOfShareOutstandingBasic
|
14076238 | shares |
| CY2022Q1 | celz |
Weighted Average Number Of Share Outstanding Basic
WeightedAverageNumberOfShareOutstandingBasic
|
6454015 | shares |
| CY2023Q1 | us-gaap |
Profit Loss
ProfitLoss
|
1051923 | usd |
| CY2022Q1 | us-gaap |
Profit Loss
ProfitLoss
|
1154869 | usd |
| CY2023Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
9162 | usd |
| CY2022Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
41360 | usd |
| CY2023Q1 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
23021 | usd |
| CY2022Q1 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
23021 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
0 | usd |
| CY2022Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-2485 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
0 | usd |
| CY2022Q1 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
3284 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-92214 | usd |
| CY2022Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
64960 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-2914116 | usd |
| CY2022Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-426181 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
0 | usd |
| CY2022Q1 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
5535 | usd |
| CY2023Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-3841642 | usd |
| CY2022Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-1576893 | usd |
| CY2023Q1 | celz |
Redemptions Of Certificates Of Deposit
RedemptionsOfCertificatesOfDeposit
|
5037326 | usd |
| CY2022Q1 | celz |
Redemptions Of Certificates Of Deposit
RedemptionsOfCertificatesOfDeposit
|
0 | usd |
| CY2023Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
5037326 | usd |
| CY2022Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
0 | usd |
| CY2023Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
0 | usd |
| CY2022Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
0 | usd |
| CY2023Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
|
1195684 | usd |
| CY2022Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
|
-1576893 | usd |
| CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
8320519 | usd |
| CY2021Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
10723870 | usd |
| CY2023Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
9516203 | usd |
| CY2022Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
9146977 | usd |
| CY2023Q1 | us-gaap |
Interest Paid Net
InterestPaidNet
|
50 | usd |
| CY2022Q1 | us-gaap |
Interest Paid Net
InterestPaidNet
|
9186 | usd |
| CY2023Q1 | us-gaap |
Income Taxes Paid Net
IncomeTaxesPaidNet
|
0 | usd |
| CY2022Q1 | us-gaap |
Income Taxes Paid Net
IncomeTaxesPaidNet
|
0 | usd |
| CY2023Q1 | celz |
Conversion Of Management Fees And Patent Liability Into Common Stock
ConversionOfManagementFeesAndPatentLiabilityIntoCommonStock
|
0 | usd |
| CY2022Q1 | celz |
Conversion Of Management Fees And Patent Liability Into Common Stock
ConversionOfManagementFeesAndPatentLiabilityIntoCommonStock
|
250000 | usd |
| CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
15864674 | usd |
| CY2023Q1 | celz |
Stock Based Compensation
StockBasedCompensation
|
9162 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-1051923 | usd |
| CY2023Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
14821913 | usd |
| CY2021Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
10217740 | usd |
| CY2022Q1 | celz |
Common Stock Issued For Related Party Patent Liabilities Amount
CommonStockIssuedForRelatedPartyPatentLiabilitiesAmount
|
250000 | usd |
| CY2022Q1 | celz |
Stock Based Compensation
StockBasedCompensation
|
41360 | usd |
| CY2022Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
9354231 | usd |
| CY2023Q1 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<p style="font-size:10pt;font-family:times new roman;margin:0px"><em><strong>Use of Estimates – </strong></em>The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> | |
| CY2017Q2 | celz |
Payments Upon Completion Of Irb Clinical Trial
PaymentsUponCompletionOfIrbClinicalTrial
|
200000 | usd |
| CY2023Q1 | us-gaap |
Deferred Revenue
DeferredRevenue
|
40000 | usd |
| CY2023Q1 | us-gaap |
Time Deposits At Or Above Fdic Insurance Limit
TimeDepositsAtOrAboveFDICInsuranceLimit
|
250000 | usd |
| CY2016Q1 | celz |
No Of Share Exchange
NoOfShareExchange
|
431111 | shares |
| CY2016Q1 | celz |
Restricted Common Stock
RestrictedCommonStock
|
100000 | usd |
| CY2023Q1 | us-gaap |
Other Intangible Assets Net
OtherIntangibleAssetsNet
|
28521 | usd |
| CY2023Q1 | celz |
Expected Amount Of Amortization
ExpectedAmountOfAmortization
|
9972 | usd |
| CY2017Q2 | celz |
Payments In The Event Of Commercialization Of Technology
PaymentsInTheEventOfCommercializationOfTechnology
|
300000 | usd |
| CY2023Q1 | celz |
Company Paid
CompanyPaid
|
50000 | usd |
| CY2020Q4 | celz |
Common Stock Issue
CommonStockIssue
|
6667 | usd |
| CY2020Q4 | celz |
Company Paid
CompanyPaid
|
50000 | usd |
| CY2020Q4 | celz |
Obligation Of The Initial Payment
ObligationOfTheInitialPayment
|
300000 | usd |
| CY2020Q4 | celz |
Common Stock Issue
CommonStockIssue
|
133 | usd |
| CY2021Q3 | celz |
Company Paid
CompanyPaid
|
40000 | usd |
| CY2021Q3 | celz |
Obligation Of The Initial Payment
ObligationOfTheInitialPayment
|
300000 | usd |
| CY2021Q3 | celz |
Common Stock Issue
CommonStockIssue
|
84656 | usd |
| CY2021Q1 | celz |
Company Paid
CompanyPaid
|
50000 | usd |
| CY2021Q1 | celz |
Obligation Of The Initial Payment
ObligationOfTheInitialPayment
|
300000 | usd |
| CY2021Q1 | celz |
Common Stock Issue
CommonStockIssue
|
89286 | usd |
| CY2023Q1 | celz |
Obligation Of The Initial Payment
ObligationOfTheInitialPayment
|
300000 | usd |
| CY2020Q4 | celz |
License Fees
LicenseFees
|
250000 | usd |
| CY2020Q4 | celz |
License Agreement Description
LicenseAgreementDescription
|
(the “Upfront Royalty”), which can also be paid in CELZ stock at a discount of 25% of the closing price of $0.0037, which is based on the date of this agreement | |
| CY2022Q1 | celz |
Number Of Share Issuance Of Common Stock To Jadi Cell
NumberOfShareIssuanceOfCommonStockToJadiCell
|
180180 | shares |
| CY2022Q4 | celz |
Licensing Agreements
LicensingAgreements
|
760000 | usd |
| CY2022Q4 | celz |
Accumulated Amortization Beginning Balance
AccumulatedAmortizationBeginningBalance
|
-324405 | usd |
| CY2023Q1 | celz |
Accumulated Amortization Addition Of New Assets
AccumulatedAmortizationAdditionOfNewAssets
|
0 | usd |
| CY2023Q1 | us-gaap |
Adjustment For Amortization
AdjustmentForAmortization
|
0 | usd |
| CY2023Q1 | celz |
Accumulated Amortization
AccumulatedAmortization
|
-23021 | usd |
| CY2023Q1 | celz |
Licensing Agreements Beginning Balance
LicensingAgreementsBeginningBalance
|
760000 | usd |
| CY2023Q1 | celz |
Accumulated Amortization Ending Balance
AccumulatedAmortizationEndingBalance
|
-347426 | usd |
| CY2022Q2 | us-gaap |
Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
|
2991669 | shares |
| CY2022Q2 | celz |
Purchase Of Warrants Shares
PurchaseOfWarrantsShares
|
4563887 | shares |
| CY2022Q2 | celz |
Purchase Of Pre Funded Warrant And Related Common Warrant
PurchaseOfPreFundedWarrantAndRelatedCommonWarrant
|
15111112 | shares |
| CY2022Q2 | celz |
Combined Offering Price Of Pre Funded Warrant And Related Common Warrant
CombinedOfferingPriceOfPreFundedWarrantAndRelatedCommonWarrant
|
2.25 | |
| CY2022Q2 | celz |
Description Of Amendment
DescriptionOfAmendment
|
pursuant to a Securities Purchase Agreement between the Company and the Purchasers dated as of April 28, 2022 (the “Purchase Agreement”), resulting in gross proceeds to the Company of approximately $17,000,000. The transaction was effected pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended and Rule 506(b) promulgated thereunder | |
| CY2023Q1 | celz |
Common Warrants Exercise Price
CommonWarrantsExercisePrice
|
2.00 | |
| CY2023Q1 | celz |
Pre Funded Warrants Exercise Price
PreFundedWarrantsExercisePrice
|
0.0001 | |
| CY2023Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | pure |
| CY2023Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P5Y | |
| CY2023Q1 | us-gaap |
Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
|
0.0081 | pure |
| CY2023Q1 | us-gaap |
Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
|
0.9295 | pure |
| CY2023Q1 | us-gaap |
Share Price
SharePrice
|
1.83 | |
| CY2022Q4 | celz |
Initial Payment Amount
InitialPaymentAmount
|
2000000 | usd |
| CY2022Q4 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
5000000 | usd |
